{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:31:52Z","timestamp":1793460712306,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"46","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,12,2]]},"DOI":"10.1038\/s41388-026-04018-x","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:45:07Z","timestamp":1792140307000},"page":"5002-5017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual novel compounds destroy mitochondrial morphology and function to treat glioblastoma by promoting the p62-mediated protein degradation of mitochondrial respiratory chain complex"],"prefix":"10.1038","volume":"45","author":[{"given":"Hanyi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-9882","authenticated-orcid":false,"given":"Qixue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunchao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-3369","authenticated-orcid":false,"given":"Chunsheng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4994-147X","authenticated-orcid":false,"given":"Xiaoteng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"4018_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329:574\u201387.","journal-title":"JAMA"},{"key":"4018_CR2","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","volume":"27","author":"PY Wen","year":"2025","unstructured":"Wen PY, Weller M, Lee EQ, Touat M, Khasraw M, Rahman R, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2025;27:2751\u201388.","journal-title":"Neuro Oncol"},{"key":"4018_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"4018_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2015.07.013","volume":"367","author":"JL Munoz","year":"2015","unstructured":"Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 2015;367:69\u201375.","journal-title":"Cancer Lett"},{"key":"4018_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41388-022-02570-w","volume":"42","author":"T Yu","year":"2023","unstructured":"Yu T, Zhou F, Tian W, Xu R, Wang B, Zeng A, et al. EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. Oncogene. 2023;42:461\u201370.","journal-title":"Oncogene"},{"key":"4018_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-19-2000","volume":"26","author":"F Higuchi","year":"2020","unstructured":"Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin Cancer Res. 2020;26:1690\u20139.","journal-title":"Clin Cancer Res"},{"key":"4018_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1743-7075-2-30","volume":"2","author":"TN Seyfried","year":"2005","unstructured":"Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab. 2005;2:30.","journal-title":"Nutr Metab"},{"key":"4018_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fcell.2017.00043","volume":"5","author":"M Strickland","year":"2017","unstructured":"Strickland M, Stoll EA. Metabolic reprogramming in Glioma. Front Cell Dev Biol. 2017;5:43.","journal-title":"Front Cell Dev Biol"},{"key":"4018_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/neuonc\/noae040","volume":"26","author":"S Yang","year":"2024","unstructured":"Yang S, Zhan Q, Su D, Cui X, Zhao J, Wang Q, et al. HIF1alpha\/ATF3 partake in PGK1 K191\/K192 succinylation by modulating P4HA1\/succinate signaling in glioblastoma. Neuro Oncol. 2024;26:1405\u201320.","journal-title":"Neuro Oncol"},{"key":"4018_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025;10:245.","journal-title":"Signal Transduct Target Ther"},{"key":"4018_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2023.100113","volume":"2","author":"Y Lin","year":"2023","unstructured":"Lin Y, Yang B, Huang Y, Zhang Y, Jiang Y, Ma L, et al. Mitochondrial DNA-targeted therapy: a novel approach to combat cancer. Cell Insight. 2023;2:100113.","journal-title":"Cell Insight"},{"key":"4018_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8532940","volume":"2021","author":"J Wang","year":"2021","unstructured":"Wang J, Sun D, Huang L, Wang S, Jin Y. Targeting reactive oxygen species capacity of tumor cells with repurposed drug as an anticancer therapy. Oxid Med Cell Longev. 2021;2021:8532940.","journal-title":"Oxid Med Cell Longev"},{"key":"4018_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106606","volume":"187","author":"F Tong","year":"2023","unstructured":"Tong F, Zhao JX, Fang ZY, Cui XT, Su DY, Liu X, et al. MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII. Pharm Res. 2023;187:106606.","journal-title":"Pharm Res"},{"key":"4018_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/neuonc\/noad159","volume":"26","author":"B Hong","year":"2024","unstructured":"Hong B, Yang E, Su D, Ju J, Cui X, Wang Q, et al. EPIC-1042 as a potent PTRF\/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma. Neuro Oncol. 2024;26:100\u201314.","journal-title":"Neuro Oncol"},{"key":"4018_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2108-x","volume":"10","author":"K Zhao","year":"2019","unstructured":"Zhao K, Cui X, Wang Q, Fang C, Tan Y, Wang Y, et al. RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFbeta pathway-dependent manner. Cell Death Dis. 2019;10:877.","journal-title":"Cell Death Dis"},{"key":"4018_CR16","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/cac2.12502","volume":"43","author":"X Cui","year":"2023","unstructured":"Cui X, Zhao J, Li G, Yang C, Yang S, Zhan Q, et al. Blockage of EGFR\/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Commun. 2023;43:1326\u201353.","journal-title":"Cancer Commun"},{"key":"4018_CR17","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1111\/febs.13540","volume":"282","author":"Y Katsuragi","year":"2015","unstructured":"Katsuragi Y, Ichimura Y, Komatsu M. p62\/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J. 2015;282:4672\u20138.","journal-title":"FEBS J"},{"key":"4018_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101674","volume":"37","author":"D Nolfi-Donegan","year":"2020","unstructured":"Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020;37:101674.","journal-title":"Redox Biol"},{"key":"4018_CR19","doi-asserted-by":"crossref","unstructured":"Fahimi P, Castanedo LAM, Vernier PT, Matta CF. Electrical homeostasis of the inner mitochondrial membrane potential. Phys Biol 2025;22:026001.","DOI":"10.1088\/1478-3975\/adaa47"},{"key":"4018_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genom Proteom Bioinform. 2022;20:587\u201396.","journal-title":"Genom Proteom Bioinform"},{"key":"4018_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"4018_CR22","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1158\/0008-5472.CAN-07-5312","volume":"67","author":"MM Alonso","year":"2007","unstructured":"Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007;67:11499\u2013504.","journal-title":"Cancer Res"},{"key":"4018_CR23","doi-asserted-by":"crossref","unstructured":"Fuchs RP, Isogawa A, Paulo JA, Onizuka K, Takahashi T, Amunugama R et al. Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide. Elife 2021;10:e69544.","DOI":"10.7554\/eLife.69544"},{"key":"4018_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mrrev.2016.05.005","volume":"769","author":"H Erasimus","year":"2016","unstructured":"Erasimus H, Gobin M, Niclou S, Van Dyck E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Rev Mutat Res. 2016;769:19\u201335.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"4018_CR25","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.7150\/thno.71763","volume":"12","author":"E Yang","year":"2022","unstructured":"Yang E, Wang L, Jin W, Liu X, Wang Q, Wu Y, et al. PTRF\/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma. Theranostics. 2022;12:4330\u201347.","journal-title":"Theranostics"},{"key":"4018_CR26","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","volume":"15","author":"S Yip","year":"2009","unstructured":"Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622\u20139.","journal-title":"Clin Cancer Res"},{"key":"4018_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119673","volume":"1871","author":"R Shaw","year":"2024","unstructured":"Shaw R, Basu M, Karmakar S, Ghosh MK. MGMT in TMZ-based glioma therapy: multifaceted insights and clinical trial perspectives. Biochim Biophys Acta Mol Cell Res. 2024;1871:119673.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"4018_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J, et al. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer. 2023;23:544.","journal-title":"BMC Cancer"},{"key":"4018_CR29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3892\/ijo.2017.3901","volume":"50","author":"K Huang","year":"2017","unstructured":"Huang K, Sun J, Yang C, Wang Y, Zhou B, Kang C, et al. HOTAIR upregulates an 18-gene cell cycle-related mRNA network in glioma. Int J Oncol. 2017;50:1271\u20138.","journal-title":"Int J Oncol"},{"key":"4018_CR30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.7150\/thno.22952","volume":"8","author":"K Huang","year":"2018","unstructured":"Huang K, Fang C, Yi K, Liu X, Qi H, Tan Y, et al. The role of PTRF\/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics. 2018;8:1540\u201357.","journal-title":"Theranostics"},{"key":"4018_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70121","volume":"30","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang H, Shang C, Hong Y. The role and applied value of mitochondria in glioma-related research. CNS Neurosci Ther. 2024;30:e70121.","journal-title":"CNS Neurosci Ther"},{"key":"4018_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s44321-025-00195-6","volume":"17","author":"A Burban","year":"2025","unstructured":"Burban A, Tessier C, Larroquette M, Guyon J, Lubiato C, Pinglaut M, et al. Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile. EMBO Mol Med. 2025;17:469\u2013503.","journal-title":"EMBO Mol Med"},{"key":"4018_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1535073","volume":"13","author":"S D\u2019Aprile","year":"2025","unstructured":"D\u2019Aprile S, Denaro S, Gervasi A, Vicario N, Parenti R. Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance. Front Cell Dev Biol. 2025;13:1535073.","journal-title":"Front Cell Dev Biol"},{"key":"4018_CR34","doi-asserted-by":"crossref","unstructured":"Kalb RC, Nyabuto GO, Morran MP, Maity S, Justinger JS, Nestor-Kalinoski AL et al. The large GTPase Guanylate-Binding Protein-1 (GBP-1) Promotes Mitochondrial Fission in Glioblastoma. Int J Mol Sci 2024;25:11236.","DOI":"10.3390\/ijms252011236"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04018-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04018-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04018-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:05:57Z","timestamp":1793459157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04018-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":34,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2026,12,2]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-04018-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest in this study. Generative AI and AI-assisted technologies were NOT used in the preparation of this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were approved by the Animal Ethics and Welfare Committee of Tianjin Medical University (No. IRB2023-DW-136). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}